Leading global genomics service provider, GENEWIZ, has signed a definitive agreement to acquire the genomic services business of Beckman Coulter, which delivers expert genomics sequencing solutions to healthcare businesses, as well as academic and government institutions worldwide (GS).
“The genomic services business of Beckman Coulter is an ideal fit with GENEWIZ’s global strategy and expansion plans,” said Dr. Steve Sun, GENEWIZ Chairman and CEO. “Our two companies share a common mission and vision, to offer scientists around the world consistently-reliable genomics service solutions that will advance innovations and scientific discoveries.”
The synergies of this acquisition will support GENEWIZ’s global expansion strategy by leveraging GS’s 25+ years of genomics expertise and capabilities. GS’s comprehensive Sanger Sequencing, Next Generation Sequencing, Bioinformatics, and CLIA/Clinical services will complement GENEWIZ’s existing genomics services. With an international presence in the U.S. and a Pan-European presence centered in the UK, GS presents an immediate opportunity to strengthen GENEWIZ’s global access and value to customers through a stronger network of global labs and office locations in the U.S., UK, China, and Japan.
“GS’s proven leadership and experienced team of industry experts have built an efficient workflow that allows for the delivery of quality and timely results to its customers,” continued Dr. Sun. “The integration of these two businesses will allow for an increased level of service and value to customers worldwide. We look forward to working with the talented GS team to best serve our customers, and be an instrumental part of the future growth of GENEWIZ.”
GS and GENEWIZ will collaboratively align to ensure there is a seamless transition for both organizations and its customer base. The agreement has been approved by the boards of directors of both companies and closed effective immediately.
Source: GENEWIZ
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
